Application: Cgri is a long-acting analogue of amylin. It is being tested to treat obestiy and type 2 diabetes by itself and in combination with semaglutide as cagri/semag. Cagri, marketed as CagriS, is a combination of cgri, a dual amylin and calcitonin receptor agonist, and SMG, a G-LP-1R agonist. It is injected once weekly and is being tested in type 2 diabetes and obestiy.Preliminary trial results found a greater weight loss compared to either medication alone.HbA1c was significantly improved compared to cagri alone and non-significantly better than smg alone. In a Phase II trial, weight loss averaged -15.6 percent after 32 weeks, making CgriS comparable in efficacy to tirz. A future trial sponsored by Novo Nordisk is comparing tirz and CagriS head-to-head.As of 2023, CagriS is in a phase III trial,compare the safety and efficacy of CagriS Injection with Smg in obese and overweight patients.
Products details
Products Name: Cgri
Cas No:N/A
Purity: >99.0%
Molecular Formula: N/A
Molecular Weight: N/A
Application: Weight loss
Appearance: White Lyophilized powder
Reconstitution: Required
Storage:After reconstitution store at 2°C - 8°C
